Comprehensive Evaluation Of Ehretia Laevis Leaf Extract: In-Vitro Enzyme Inhibition, Anti-Oxidant Activities, And In-Vivo Anti-Diabetic Effects In Stz-Induced Diabetic Rats

In this study, we have aimed to detail evaluation for in-vitro and in–vivo enzyme inhibitory, antioxidant potential of leaf extracts of Ehretia laevis for the development anti-diabetic drug. In-vitro activity was tested using standards protocols for ant diabetic studies especially alpha-amylase and alpha-glucosidase inhibitory activities. DPPH assay for Antioxidant Activity STZ-induced diabetic albino rats were used to evaluate in-vivo anti-diabetic efficacy. Animals were divided into 7 groups, of which normal control group (NC), diabetic control group(DC) and treated with metformin as standard drug; test animals L1 in hexane fraction at three doses 100 mg/kg/day bwt, 200 &300mg/kg/d after confirmation was given for the period of approx seven days to study its toxic effect. This include blood sugar levels, serum lipid profile, liver function (SGOT &SGPT) and kidney function test.  Inhibitory potential of L2 (higher potency) in α-amylase & α-glucosidase were significant as compare to extracts from L1 Table 7. The antioxidant potential test has been shown to have a significant DPPH scavenging activity. Hypolipidemic, hypoglycemic and anti-acetylcholinesterase activities also were demonstrated in extract treated groups which was accompanied by a significant reduction of blood glucose level; lipid profile improvement including liver enzymes normalization detected on the study using in-vivo. HPTLC analysis proved the presence of β-sitosterol and gallic acid. Leaves extracts of E. laevis have a marked antihyperglycemic, enzymes inhibitory and antioxidant activity that could be worthy for management of diabetes mellitus complications in the public health service arenas are feasible as natural therapeutic agents due to popular use with minimal side effects on patients.